Rituximab is noninferior to ocrelizumab in suppressing T2-weighted MRI lesions from month 6 to 24
Trial shows rituximab works as well as ocrelizumab for MS
This Phase 3 randomized controlled trial of 218 adults with newly diagnosed relapsing multiple sclerosis found rituximab noninferior to ocre…
A new study finds that two different treatments for multiple sclerosis show similar success in stopping brain lesions and managing disease a…
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS
Cladribine tablets show promise for managing relapsing-remitting multiple sclerosis
This systematic review and network meta-analysis of 66 studies evaluated cladribine against various disease-modifying treatments for relapsi…
New data shows cladribine tablets significantly reduce relapse rates and slow disease progression in people with active relapsing-remitting …
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS
High-dose ocrelizumab did not further reduce disability progression in multiple sclerosis patients
This phase 3b randomized controlled trial in 860 and 753 patients with relapsing or primary progressive multiple sclerosis found that high-d…
A large trial found that higher doses of ocrelizumab did not lower the risk of disability progression compared to the standard dose in multi…
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
This phase 3b trial evaluated intravenous ocrelizumab versus placebo in patients with primary progressive multiple sclerosis. The study foun…
A large trial found ocrelizumab significantly lowers the risk of disability progression in patients with primary progressive multiple sclero…
Marburg MS case shows treatment challenges and fatal outcome
A Rare MS Variant Defied Treatment Until This Switch
A 46-year-old woman with aggressive Marburg MS faced treatment-limiting toxicity and died despite multiple therapies, highlighting urgent ca…
A woman with a rare, aggressive form of multiple sclerosis tried many treatments without success, and doctors tried a new approach too late.
Ocrelizumab treatment in multiple sclerosis shows disability improvement in relapsing forms
MS Drugs Stop Relapses But Miss This Silent Disability Threat
This retrospective longitudinal cohort study analyzed 1859 people with multiple sclerosis treated with ocrelizumab. Disability improvement w…
• Top MS drugs fix sudden relapses but not slow nerve damage • Helps people with all MS types facing hidden progression • Not a new treatmen…
High-dose melatonin linked to hepatotoxicity in small PP-MS trial, prompting early halt
High-dose melatonin trial halted after liver safety concerns in MS patients
A phase I/II RCT of 8 patients with PP-MS on stable ocrelizumab found that adjunctive high-dose oral melatonin (300 mg/day) was associated w…
A high-dose melatonin trial for multiple sclerosis stopped early after three of four patients developed mild liver injury, though the issue …